Tonix Pharmaceuticals to Present at Cantor 2026 Global Healthcare Conference

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at the Cantor 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., is set to present on September 10 from 3:55 to 4:25 p.m. ET, with a live webcast and replay accessible through the Investors section of the Tonix website. This engagement provides an opportunity for investors to gain insights into the company's strategic direction and recent developments.

The announcement comes at a pivotal time for Tonix, as the company recently received approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. This approval marks a significant milestone for the company, positioning it as a commercial-stage biotechnology firm with a focus on central nervous system (CNS) and immunology treatments. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra, which contribute to its revenue stream.

Beyond its commercial products, Tonix is actively expanding the clinical utility of TONMYA through Phase 2 trials evaluating its potential in major depressive disorder and acute stress disorder. Additionally, the company's CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease with limited therapeutic options. In the immunology space, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.

These pipeline programs highlight Tonix's commitment to addressing areas of high unmet medical need. The company's participation in the Cantor conference is expected to draw attention from investors and industry analysts, particularly given the recent approval of TONMYA and the potential of its pipeline candidates. The conference serves as a platform for Tonix to articulate its vision and operational progress, which could influence market perception and investor confidence.

Tonix's strategic focus on CNS and immunology aligns with broader industry trends toward specialized therapies for chronic and rare conditions. The approval of TONMYA addresses a long-standing gap in fibromyalgia treatment, potentially benefiting a substantial patient population. Meanwhile, the development of TNX-1500 for kidney transplant rejection could address a critical need in transplantation medicine, where current therapies have significant limitations.

As Tonix continues to execute its commercial and clinical strategies, its presence at major healthcare conferences like Cantor's underscores its active engagement with the investment community. The live webcast and replay of the presentation will ensure broad accessibility for stakeholders, reinforcing the company's commitment to transparency. With a robust pipeline and a newly approved product, Tonix is poised to leverage these opportunities to drive growth and deliver value to patients and shareholders alike.